Pfizer CEO took on COVID. Now he wants to cure cancer | Titans and Disruptors

Key Concepts

• Public-Private Collaboration: The crucial role of partnership between government and private companies, particularly highlighted during the COVID-19 pandemic.
• Patent Cliff: The expiration of patents on blockbuster drugs, leading to generic competition and potential revenue loss for pharmaceutical companies.
• GLP-1s: A class of drugs initially for diabetes, now gaining prominence for weight loss, representing a new growth area for Pfizer.
• AI in Drug Discovery: The application of artificial intelligence and machine learning to accelerate and improve the process of identifying and developing new drugs.
• Tiered Pricing: A pricing strategy for pharmaceuticals that offers different prices based on a country’s income level.
• Manufacturing Scale-Up: The rapid and massive increase in production capacity, exemplified by Pfizer’s COVID-19 vaccine manufacturing.
• PBMs (Pharmacy Benefit Managers): Intermediaries in the pharmaceutical supply chain that negotiate drug prices with manufacturers and manage prescription drug benefits for health plans.
• National Security & Pharmaceutical Competition: The growing competition between the US and China in the biomedical research and pharmaceutical industries.

The Fortune 500 Titan: Albert Bourla and Pfizer’s Future

Introduction

This discussion with Albert Bourla, CEO of Pfizer, explores his leadership during the COVID-19 pandemic, the company’s strategic shifts, and its future ambitions in oncology, obesity treatment, and leveraging artificial intelligence. The conversation, conducted by Allison Shantel, delves into Bourla’s upbringing, Pfizer’s response to the pandemic, the challenges of the patent cliff, and the evolving landscape of the pharmaceutical industry.

I. Early Life and Leadership Foundation

Albert Bourla attributes his leadership style and drive to his upbringing in a middle-class family with parents who were Holocaust survivors. His father instilled a love for science, while his mother fostered resilience and optimism, emphasizing that “nothing is impossible.” His mother’s harrowing experience – being spared execution at the last moment – shaped her worldview and instilled in Bourla a belief in the miraculous nature of life and the power of perseverance. He joined Pfizer in Greece in 1993, initially intending a sabbatical from academia, but found fulfillment in the dynamism and creativity of the private sector. Early international assignments fostered cultural sensitivity and an understanding of the importance of diversity.

II. Pfizer’s Transformation and the COVID-19 Response

Bourla spearheaded a significant transformation of Pfizer, shifting its focus from a diversified business to a purely science-based, innovation-driven company. This involved divesting non-scientific businesses, increasing R&D investment, and embracing digital technologies. This strategic repositioning proved crucial during the COVID-19 pandemic.

Pfizer’s response to the pandemic was characterized by unprecedented speed and collaboration. Bourla recounts frequent calls with President Trump, and a dedicated team working “around the clock” to develop the first FDA-approved COVID-19 vaccine and treatment (Paxlovid). He highlights the remarkable scale-up of vaccine production from 200 million doses annually to 3 billion in a single year. Bourla emphasized a leadership approach focused on motivating his team by framing the urgency of the situation: “Time is life.” He candidly admits to using what he calls “emotional blackmail,” urging his team to calculate the lives lost with even a short delay, to drive them to overcome seemingly impossible challenges. He noted that people stopped trying to explain why something couldn’t be done and instead focused on how to make it happen.

III. Navigating Post-Pandemic Challenges: Patent Cliff and Revenue Diversification

While the COVID-19 pandemic brought record revenues to Pfizer (reaching $100 billion in sales in 2022), the subsequent decline in demand for vaccines and treatments has created new challenges. The company faces a “patent cliff,” with key patents on lucrative drugs expiring in the coming years, opening the door to generic competition.

Bourla outlines a strategy to address these challenges through significant investments ($23 billion) in new business development opportunities, rebuilding commercial operations, and focusing on key growth areas. He anticipates a return to strong growth by 2029-2030, driven by innovation in oncology and obesity treatment.

IV. Strategic Focus: Oncology, Obesity, and the Matsera Acquisition

Pfizer is prioritizing oncology, allocating over 40% of its $11 billion annual R&D budget to cancer research. The acquisition of Seagen (Matsera), after a competitive bidding war with Novo Nordisk, is a key component of this strategy. Bourla describes the acquisition process as a “Game of Thrones,” involving intense negotiations and a last-minute scramble to secure the deal.

The company is also pursuing opportunities in obesity treatment, initially with GLP-1s. While early internal programs faced setbacks due to liver toxicity, the acquisition of Matsera positions Pfizer to compete in this rapidly growing market.

V. The Role of AI and the Future of Drug Discovery

Bourla emphasizes the transformative potential of artificial intelligence (AI) in drug discovery and development. He cites the example of Paxlovid, where AI-driven molecular design reduced the preclinical development time from four years to four months. He believes that AI will accelerate the entire drug development process, from target identification to clinical trials. He stresses the importance of organizational transformation to fully leverage AI’s capabilities, emphasizing the need to embrace optimism and overcome resistance to change.

VI. Global Competition and the US Pharmaceutical Landscape

Bourla expresses concern about the growing competition from China in the biomedical research and pharmaceutical industries. He argues that the US should focus on strengthening its own innovation ecosystem rather than solely attempting to slow down China’s progress. He highlights China’s increasing scientific output and investment in biotech, emphasizing the need for the US to maintain its leadership position.

He also addresses the issue of drug pricing in the US, acknowledging the need for affordability and transparency. He details a recent agreement with the Trump administration to offer discounted drug prices, while also pointing to the role of Pharmacy Benefit Managers (PBMs) in driving up costs.

VII. Leadership Philosophy and Future Outlook

Bourla concludes by sharing his leadership philosophy, emphasizing the importance of balancing optimism with realism. He believes that great achievements require both visionaries and pragmatists, and that leaders must inspire their teams to overcome challenges and pursue ambitious goals. He predicts significant advancements in cancer treatment, potentially transforming it into a chronic manageable disease, and breakthroughs in neuroscience, addressing conditions like Alzheimer’s and Parkinson’s.

Notable Quotes:

• “Nothing great on this earth has been accomplished without an optimist behind it.” – Albert Bourla
• “Pessimists are usually right. But nothing great on this earth has been accomplished without an optimist behind it.” – Albert Bourla
• “Time is life.” – Albert Bourla (used as a guiding principle during the COVID-19 pandemic)
• “You need to exceed yourself. You need to use ingenuity. Don't try to convince me why you cannot make it. Try to find ways to make it happen.” – Albert Bourla (on motivating his team during the vaccine development)

Conclusion

Albert Bourla’s leadership at Pfizer has been marked by bold strategic decisions, a relentless focus on innovation, and a commitment to addressing global health challenges. The company’s response to the COVID-19 pandemic demonstrated the power of public-private collaboration and the importance of rapid innovation. As Pfizer navigates the challenges of the patent cliff and a changing pharmaceutical landscape, its focus on oncology, obesity treatment, and AI-driven drug discovery positions it for continued growth and impact. Bourla’s emphasis on optimism, resilience, and a willingness to embrace change provides valuable insights for leaders across all industries.